Navigation Links
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
Date:11/9/2011

THE WOODLANDS, Texas, Nov. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center will be presenting data from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at the annual meeting of the American College of Rheumatology on Wednesday, November 9, 2011 in Chicago, Illinois.  LX2931 is an orally-administered small molecule designed to inhibit sphingosine-1-phosphate lyase (S1P), an enzyme in a pathway known to be important in regulating the immune response.  

Results from the Phase 2a study demonstrated a favorable safety profile at all doses tested and suggested that patients with rheumatoid arthritis treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX2931, including characterizations of the results of and projected timing of clinical trials of LX2931, and the potential therapeutic and commercial potential of LX2931. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX2931 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
3. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
6. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
7. Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... , ... "I had a terrible time trying to get my grandson to ... the nebulizer had a more child-friendly design, then children would be more likely to ... NEBY to avoid the need to deliver medication via a nebulizer mask. The design ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
Breaking Medicine News(10 mins):